Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Studies demonstrate real-world clinical utility of EsoGuard testing to detect esophageal precancer
NEW YORK, Dec. 12, 2023 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today announced that three manuscripts providing interim results from the Prospective REView of Esophageal Precancer DetectioN in AT-Risk Patients (PREVENT) Registry, the CLinical Utility of EsoGuard (CLUE) study, and full data from the San Antonio Firefighter study, have been published—the first peer-reviewed publications demonstrating real-world clinical utility of Lucid’s EsoGuard® Esophageal DNA test to detect esophageal precancer.
Related news for (LUCD)
- Lucid Diagnostics Announces Closing of Public Offering of Common Stock
- Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
- Lucid Diagnostics Announces Proposed Public Offering of Common Stock
- Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
- Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025